Literature DB >> 3754266

Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin.

P C Fuchs, R N Jones, A L Barry, C Thornsberry.   

Abstract

A total of 750 bacterial isolates, including 37 different species, were tested for susceptibility to BMY-28142 by standardized broth microdilution and disk diffusion tests. The zone diameter interpretive criteria tentatively suggested for the 30-micrograms BMY-28142 disk are as follows: susceptible = greater than or equal to 18 mm (MIC less than or equal to 8.0 micrograms/ml), resistant = less than or equal to 14 mm (MIC greater than or equal to 32 micrograms/ml), and indeterminate = 15 to 17 mm.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3754266      PMCID： PMC268712          DOI： 10.1128/jcm.23.3.634-636.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  6 in total

1.  In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains.

Authors:  C N Baker; C Thornsberry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

2.  Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.

Authors:  P C Fuchs; R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

3.  In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin.

Authors:  R N Jones; C Thornsberry; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

4.  In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.

Authors:  A Tsuji; A Maniatis; M A Bertram; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

5.  Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins.

Authors:  N J Khan; J A Bihl; R F Schell; J L LeFrock; S J Weber
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

6.  Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories.

Authors:  R N Jones; C Thornsberry; A L Barry; L Ayers; S Brown; J Daniel; P C Fuchs; T L Gavan; E H Gerlach; J M Matsen
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948
  6 in total
  5 in total

1.  Preliminary interpretive criteria for the Haemophilus Test Medium method using 30 micrograms cefepime disks.

Authors:  R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

2.  Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients.

Authors:  D Yamamura; R Gucalp; P Carlisle; M Cimino; J Roberts; C Rotstein
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Interpretive criteria for the agar diffusion susceptibility test with ofloxacin.

Authors:  H Grimm
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Development of test panel of beta-lactamases expressed in a common Escherichia coli host background for evaluation of new beta-lactam antibiotics.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

Review 5.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.